CureDuchenne Blog

There’s No Straight Line in Drug Development

Today’s FDA disapproval of Sarepta’s Vyondys 53 is disheartening, but a true example of just how difficult and costly the drug development process is.  We appreciate Sarepta’s efforts and dedication […]

Updates on CureDuchenne Gene Therapy Initiative

We are excited to report the progress of CureDuchenne’s Gene Therapy Initiative.  From our investment, as early as 2010, in Nationwide Children’s permanent duplication2 skipping program, to what has become […]